Here's how aggressive traders could play this biotech giant -- and our targets for the name.
This quartet has had a rough 2021 but could be in for a rebound next year once investors harvest their losses in the shares.
The bulls are back in charge.
Here's our next price target.
The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
Eyenovia and BioDelivery Sciences are their targets.
Plus, the headline numbers don't come close to telling the story of Thursday's action in the equity markets, which had a case of bad breadth.
J&J will be separating into two distinct firms, but not right away.